SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to concerns about AI sales performance following a report of lowered sales quotas, which the company disputes; this has sparked debate about the strength of its AI offerings and competition from Google's Gemini. Community discussion includes frustration over the stock's price action relative to peers and broader market indices, with some viewing the dip as a buying opportunity while others express skepticism about the company's AI strategy and overall valuation. Some traders point out that a correction back to the 450 or even 300 levels may occur before eoy.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to positive Phase 3 HOPE-3 trial results for their DMD treatment, deramiocel, leading to significant community excitement and a potential short squeeze. The community is focused on the implications of the data, potential FDA approval, and the possibility of a buyout, while also targeting short-sellers. With strong results in both skeletal and cardiac function, CAPR is seen as a promising player in the DMD treatment landscape.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Recent reports suggest Netflix is vying for Warner Bros. Discovery assets, sparking community discussion around potential synergies and regulatory hurdles. The community is weighing the implications of Netflix potentially acquiring the studio and streaming service, including debates on content libraries and market dominance. Amidst these acquisition talks, there are also discussions on the stock's recent performance and future price movement, with some traders expressing bearish sentiments.

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Polyrizon Ltd. Ordinary Shares

Polyrizon (PLRZ) is trending due to positive news regarding its nasal spray manufacturing milestone and superior mucoadhesion results, sparking significant after-hours momentum. The community is actively discussing its potential as a multi-day runner and comparing it to other low-float Israeli stocks that have recently experienced substantial gains. Some traders, however, express concern about a potential dilution pump.

UP Fintech Holding Ltd. is an online brokerage firm that focuses on global investors. It provides an online trading platform that enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The firm offers products and services, as well as a user experience to customers through its mobile first strategy. The company was founded by Tian Hua Wu in June 2014 and is headquartered in Singapore.

UP Fintech Holding Ltd - ADR

UP Fintech Holding (TIGR) is trending following a strong earnings report, with revenue and net income seeing significant year-over-year growth. Community members are impressed by the results, drawing comparisons to other brokerage platforms and anticipating a potential surge in stock price. Despite positive financials, some express concerns about the company's association with Chinese stocks and the lack of an earnings date, leading to volatility.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending amid speculation and excitement around the robotics sector, driven by potential government support and company-specific developments like overnight trading highs and high trading volumes. Community members are actively discussing potential short squeezes and comparing SERV to other robotics plays, anticipating further gains and focusing on the company's growth prospects with its DoorDash partnership. Some see a buying opportunity, while others are wary, pointing to past volatility and dilution.

IMX is the native token for the Immutable X network, the first zk-rollup for NFT on Ethereum.

Immutable X

Immutable X is trending as community members discuss its bullish structure and potential for near-term gains, citing spot-driven volume and relative strength against Bitcoin. A new gaming hub launch on Polygon with quests and rewards also appears to be a factor, alongside discussion of staking rewards. Some traders are noting overbought conditions and upcoming token releases as potential risks.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending amid discussions around its acquisition of Spirit AeroSystems and the FTC's required divestitures to address antitrust concerns; community sentiment appears mixed. Some traders are bullish, anticipating a rise to $300, while others express concern over debt and past issues, viewing the stock as manipulated. There's also discussion around potential impacts from Airbus and general sector outlook.

Virtuals Protocol is a launchpad platform launched in 2024 that enables users to create, tokenize, and monetize AI agents for gaming, entertainment, and virtual environments without requiring technical expertise. Initially built on Ethereum's Base Layer 2 network, the protocol has expanded to Ethereum mainnet, Solana, and Ronin as of 2025. VIRTUAL serves as the base liquidity pair and transactional currency for all AI agent interactions across the ecosystem.  The protocol operates through a bonding curve system where new AI agents are created with a 100 VIRTUAL fee. Users can buy and sell agent tokens until the agent reaches 42,000 VIRTUAL, at which point it graduates to a permanent liquidity pool paired with VIRTUAL. AI agents are multimodal, capable of text, speech, and 3D animation, and can manage on-chain wallets autonomously. Notable examples include Luna, an AI girl band vocalist with over 500,000 TikTok followers. The GAME framework powers agent functionality, enabling them to process inputs, generate responses, and remember past interactions.  Virtuals Protocol was founded by Jansen Teng and Weekee Tiew, evolving from PathDAO, a gaming guild established in 2021 that pivoted to AI agents in January 2024. The team raised $16 million in seed funding led by DeFiance Capital and Beam. In 2025, major partnerships were announced with Animoca Brands and a collaboration with Zyfai and BasisOS to launch an Agentic Fund of Funds.  Users can stake VIRTUAL tokens for veVIRTUAL to participate in DAO governance and may receive airdrops of agent tokens. When users interact with agents, they pay fees in VIRTUAL that generate protocol revenue. This revenue funds periodic buybacks and burns of the VIRTUAL token, reducing its total supply as a value-accrual mechanism for holders.

Virtual Protocol

Virtual Protocol is trending as the community discusses its potential as a leader in AI agents, particularly after a recent rebound where whales aggressively defended a key price level.  Enthusiasm is fueled by the launchpad going live, increased smart money accumulation, and speculation around potential investments, with some anticipating a significant price increase by January. The focus is on Virtual Protocol as the potential 'App Store for AI Agents'.

PRIME is the native token of the Echelon Prime Foundation, a Web3 ecosystem advancing the next generation of gaming. Echelon creates and distributes tools to encourage innovation in, and promote the growth of, novel gaming models and economies. The first game to adopt and utilize PRIME is Parallel, a sci-fi trading card game.

Echelon Prime

Echelon Prime ($PRIME) is gaining attention as traders discuss its recent price movements and potential for further gains, with some eyeing specific price targets. Community members are pointing to its position as a gaming token supporting Web3 expansion. The coin's association with AI is also brought up by users.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH PR Newswire NASHVILLE, Tenn., Nov. 4, 2025 NASHVILLE, Tenn., Nov...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE PR Newswire NASHVILLE, Tenn., Oct...

CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC. CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn., Feb. 25, 2025 NASHVILLE, Tenn...

VIBATIV RECEIVES MARKETING APPROVAL IN CHINA

VIBATIV RECEIVES MARKETING APPROVAL IN CHINA VIBATIV RECEIVES MARKETING APPROVAL IN CHINA PR Newswire NASHVILLE, Tenn. and SHANGHAI, Feb. 18, 2025 Vibativ is a life-saving antibiotic for pneumonia...

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease Cumberland Pharmaceuticals Announces Breakthrough Results from...

Shares of Cumberland Pharmaceuticals (CPIX) doubled on Tuesday morning, reaching levels not seen since March 2023, following FDA approval of a new dosing regimen for its liver drug, Acetadote.Acetadote, an intravenous formulation of N-acetylcysteine, helps prevent or mitigate liver injury caused by toxic acetaminophen ingestion.&nbsp;The newly approved regimen combines the first two standard doses into a single, slower infusion, simplifying administration and improving patient outcomes, according to experts.Rick Dart, MD, PhD, Director at the Rocky Mountain Poison and Drug Center, said: "By streamlining the administration of NAC, we can improve patient outcomes and reduce the risk of adverse events. This simplified dosing regimen is a valuable tool for health care providers in managing this potentially life-threatening condition."<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CPIX_sentiment_and_message_volume_Dec_10_64a13aec8e.png" alt="CPIX sentiment and message volume Dec 10.png" width="1318" height="324"><figcaption>CPIX sentiment and message volume Dec 10 as of 10:15 am ET | Source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for Cumberland shot up into ‘extremely bullish’ territory amid a surge in message volume.One user called the latest development “too much big news” to keep the stock between $5-$10 for long.<stembedurl>https://stocktwits.com/cjstocksup/message/595845075</stembedurl>Cumberland has attracted significant retail attention on Stocktwits, with watchlist growth of over 7% and message activity surging by 9,000% in the past year.In addition to Acetadote developments, Cumberland is advancing several Phase II clinical programs evaluating ifetroban, a drug candidate targeting conditions like cardiomyopathy associated with Duchenne Muscular Dystrophy, systemic sclerosis, and idiopathic pulmonary fibrosis.<a href="https://stocktwits.com/symbol/CPIX">Cumberland shares</a> are up nearly 26% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Cumberland Pharma Stock Hits 16-Month High After FDA Approves Liver Drug Regimen: Retail’s Thrilled

The newly approved regimen combines the first two standard doses into a single, slower infusion, simplifying administration and improving patient outcomes, according to experts.

Equity

FDA APPROVES ACETADOTE sNDA

FDA APPROVES ACETADOTE sNDA FDA APPROVES ACETADOTE sNDA PR Newswire NASHVILLE, Tenn., Dec. 9, 2024 - New Dosing Regimen Simplifies Administration - NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire...

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update PR Newswire...

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND...

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

CPIX
Cumberland Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings:

Historical Earnings

Latest CPIX News

CPIXCumberland Pharmaceuticals Inc.